Clinical Trial Update: Study of Efficacy and Safety of Vortioxetine (Lu AA21004) in Treating Generalized Anxiety Disorder [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating vortioxetine (Lu AA21004) for generalized anxiety disorder has completed, with results posted in 2013. The update summarizes efficacy…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Generalized Anxiety Disorder

Drugs mentioned

• Vortioxetine (vortioxetine)

Snippet

Sponsor: Takeda | Conditions: Generalized Anxiety Disorder | Phase 3 | Status: COMPLETED | Results posted: 2013-12-18